[go: up one dir, main page]

AU2017260873B2 - Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases - Google Patents

Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases Download PDF

Info

Publication number
AU2017260873B2
AU2017260873B2 AU2017260873A AU2017260873A AU2017260873B2 AU 2017260873 B2 AU2017260873 B2 AU 2017260873B2 AU 2017260873 A AU2017260873 A AU 2017260873A AU 2017260873 A AU2017260873 A AU 2017260873A AU 2017260873 B2 AU2017260873 B2 AU 2017260873B2
Authority
AU
Australia
Prior art keywords
steroid
cbd
dose
subject
functional derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017260873A
Other languages
English (en)
Other versions
AU2017260873A1 (en
Inventor
Sari Prutchi SAGIV
Moshe YESHURUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stero Biotechs Ltd
Original Assignee
Stero Biotechs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/143,694 external-priority patent/US9889100B2/en
Application filed by Stero Biotechs Ltd filed Critical Stero Biotechs Ltd
Publication of AU2017260873A1 publication Critical patent/AU2017260873A1/en
Application granted granted Critical
Publication of AU2017260873B2 publication Critical patent/AU2017260873B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017260873A 2016-05-02 2017-05-01 Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases Active AU2017260873B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/143,694 US9889100B2 (en) 2013-05-02 2016-05-02 Cannabidiol for treatment of severe and refractory graft-versus-host disease
US15/143,694 2016-05-02
PCT/IL2017/050483 WO2017191630A1 (fr) 2016-05-02 2017-05-01 Cannabidiol utilisé pour réduire une dose de stéroïde et pour traiter des maladies inflammatoires et auto-immunes

Publications (2)

Publication Number Publication Date
AU2017260873A1 AU2017260873A1 (en) 2018-11-29
AU2017260873B2 true AU2017260873B2 (en) 2023-03-02

Family

ID=60203614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017260873A Active AU2017260873B2 (en) 2016-05-02 2017-05-01 Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases

Country Status (7)

Country Link
EP (1) EP3452046A4 (fr)
KR (1) KR102537990B1 (fr)
CN (2) CN109414443A (fr)
AU (1) AU2017260873B2 (fr)
CA (1) CA3022900A1 (fr)
IL (1) IL262713B2 (fr)
WO (1) WO2017191630A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265574A1 (en) * 2013-05-02 2022-08-25 Stero Biotechs Ltd. Methods of using cannabidiol and a steroid
CN119632928A (zh) 2019-10-03 2025-03-18 耶路撒冷希伯来大学伊森姆研究发展有限公司 数个脂质体大麻素及其用途
EP4072558A4 (fr) * 2019-12-13 2023-12-20 Buzzelet Development And Technologies Ltd Compositions et procédés pour le traitement de l'inflammation avec des stéroïdes et un modulateur
AU2021223191A1 (en) * 2020-02-19 2022-10-13 MERCHANT, Shreema Compositions and therapeutic uses of cannabidiol
IL301161A (en) * 2020-09-06 2023-05-01 Medicane Res & Development Ltd The composition including cannabinoids and/or terpenes and methods for using it
CN113398104B (zh) * 2021-07-14 2022-04-08 北京森宏健康科技有限公司 大麻二酚在治疗胆红素脑病中的用途
WO2023058016A1 (fr) * 2021-10-04 2023-04-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Médicaments anti-inflammatoires non stéroïdiens et cannabinoïdes et leurs utilisations
WO2025107042A1 (fr) * 2023-11-22 2025-05-30 Algorae Pharmaceuticals Ltd Compositions et méthodes pour le traitement ou la prévention de maladies ou de troubles cardiovasculaires

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274635B1 (en) * 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
US20090005461A1 (en) * 2007-06-18 2009-01-01 University Of South Carolina Use of Cannabidiol in the Treatment of Hepatitis
US20110195096A1 (en) * 2008-07-31 2011-08-11 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US9889100B2 (en) * 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274635B1 (en) * 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
US20090005461A1 (en) * 2007-06-18 2009-01-01 University Of South Carolina Use of Cannabidiol in the Treatment of Hepatitis
US20110195096A1 (en) * 2008-07-31 2011-08-11 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders

Also Published As

Publication number Publication date
EP3452046A4 (fr) 2020-02-19
IL262713B1 (en) 2024-03-01
CN109414443A (zh) 2019-03-01
KR20190016952A (ko) 2019-02-19
IL262713A (en) 2018-12-31
IL262713B2 (en) 2024-07-01
WO2017191630A1 (fr) 2017-11-09
AU2017260873A1 (en) 2018-11-29
CA3022900A1 (fr) 2017-11-09
CN117017998A (zh) 2023-11-10
EP3452046A1 (fr) 2019-03-13
KR102537990B1 (ko) 2023-05-30

Similar Documents

Publication Publication Date Title
AU2017260873B2 (en) Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
JP2022064988A (ja) カンナビジオールによる脆弱x症候群の処置
CN109152774A (zh) 眼部炎性病症和疾病的组合治疗
US11357740B2 (en) Cannabidiol for enhancing the therapeutic effect of a steroid
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
EP2723330B1 (fr) Agent de polythérapie contenant des vasoconstricteurs
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
CN113274342B (zh) 一种秋水仙碱外用组合物
US10660865B2 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および/または予防剤
EP2808025B1 (fr) Composition pharmaceutique et produit cosmétique quasi-médicamenteux utilisant celle-ci
WO2020106191A1 (fr) Production de glutarimide pour vaincre la résistance aux stéroïdes
CN114515293A (zh) 一种毛蕊花糖苷在制备治疗雄激素性脱发药物中的应用
Ponticelli et al. The pharmacology of old and new agents for specific therapy of primary glomerular diseases
US20250099472A1 (en) Ruxolitinib for the treatment of prurigo nodularis
CN110891580A (zh) 使用三氧化二砷治疗多发性硬化症的方法
US20140378426A1 (en) Methods and compositions for enhancing visual function
WO2025018279A1 (fr) Agent thérapeutique contre une maladie du greffon contre l'hôte humain et combinaison associée
US6277834B1 (en) Agents for relieving side effects of adrenal cortex hormone
WO2025096373A1 (fr) Ruxolitinib destiné à être utilisé dans le traitement du prurigo nodulaire
US20220265574A1 (en) Methods of using cannabidiol and a steroid
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
MX2014012904A (es) Carboxamidas y sus sales farmaceuticamente aceptables para usarse en el tratamiento de dermatosis sensibles a esteroides.
KR20010032771A (ko) 크로모글릭산 화합물의 의약 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)